News from Shionogi Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 02, 2015, 08:03 ET Shionogi Inc. Initiates Phase 3 Clinical Study Of Osphena® For The Treatment Of Postmenopausal Vaginal Dryness

 Shionogi Inc. announced today the company has initiated a Phase 3 clinical trial to evaluate the safety and efficacy of Osphena®...


Sep 08, 2015, 14:31 ET New Shionogi Inc. Advertising Campaign Features A Personal Story About Painful Sex After Menopause

 There are many women in the U.S. who experience moderate to severe painful sex due to menopause, and very few are discussing it with their...


Oct 09, 2014, 14:00 ET Novel Siderophore Cephalosporin S-649266 Pre-Clinical Results Suggest Potent Activity Against Multidrug-Resistant Gram-Negative Pathogens

S-649266, an investigational parenteral siderophore cephalosporin, exhibits marked potency against Gram-negative bacteria, including...


Oct 01, 2014, 09:00 ET Shionogi Inc. Announces Four Abstracts To Be Presented At The 25th Annual Meeting Of The North American Menopause Society (NAMS) In Washington, DC

Shionogi Inc., a global leader dedicated to women's health, will unveil four abstracts containing new analyses and safety and efficacy data from...


Sep 04, 2014, 09:00 ET Shionogi Inc. Pledges to "Take Charge" in Honor of Menopause Awareness Month

This September, Shionogi Inc. supports the Women's Health Foundation with a five dollar donation for every pledge taken on WomenTakeCharge.com....


Jul 03, 2014, 09:00 ET It's Time to Talk about Sex After Menopause, A New Campaign To Free Women From The Silence Around An Often-Neglected Area Of Women's Health

 Beginning July 4th, women, men and health care providers are encouraged to lend their social voices to an often-neglected area of women's...


Jan 13, 2014, 09:00 ET Shionogi Inc. Announces Co-Promotion Agreement with Noven Pharmaceuticals For Brisdelle™ (Paroxetine) Capsules

 Shionogi Inc. today announced that it has entered into an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote...


Jun 25, 2013, 06:30 ET Actress Virginia Madsen Partners With Shionogi Inc. To Empower Postmenopausal Women To Break The Silence Around Painful Intercourse Due To Menopause

Academy Award-nominated actress Virginia Madsen is never one to shy away from a conversation, even if the topic at first blush seems awkward or...


May 16, 2013, 11:03 ET New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy

 A new survey of more than 3,000 postmenopausal women reveals that women living with vulvar and vaginal atrophy (VVA) are either unaware of...


Feb 26, 2013, 15:10 ET Shionogi Receives FDA Approval For Osphena™ (Ospemifene) For The Treatment Of Dyspareunia, A Symptom Of Vulvar And Vaginal Atrophy (VVA), Due To Menopause

 Shionogi Inc., the United States (U.S.)-based company of Shionogi & Co., Ltd., today announced that the U.S. Food and Drug Administration...


Jan 25, 2012, 08:00 ET Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions

 Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced results from two studies published online today in...


Aug 04, 2011, 08:00 ET Head Lice Returns to School: Five Tips to Avoid Panic and Worry

It's back-to-school season and for many families, that means new morning routines, homework and head lice. To view the multimedia assets...


May 09, 2011, 08:00 ET Shionogi Inc. Announces Publication of Data in Pediatrics Demonstrating Efficacy of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets as Add-On Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the publication in Pediatrics of data demonstrating the...


Apr 07, 2011, 08:00 ET Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™...


Jan 10, 2011, 08:20 ET Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial...


Oct 04, 2010, 08:00 ET Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of the...


Jul 29, 2010, 08:22 ET Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of...